Revacept in Symptomatic Carotid Stenosis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.
Also called NCT01645306
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 158 participants
- Sponsor
- AdvanceCor GmbH
- Registry
-
NCT01645306
-
- Other papers using this trial's data
- Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Germany, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01645306. Randomized; quadruple masking; primary purpose treatment. Start 2013-03-08 (actual); primary completion 2018-10-05 (actual). Results posted on 2021-01-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Revacept in Symptomatic Carotid Stenosis
- Acronym
- RevaceptCS02
- Condition
- Carotid Stenosis
- Condition
- Atherosclerosis
- Condition
- Stroke
- Condition
- Transient-ischaemic Attack
- Condition
- TIA (transient ischemic attack)
- Condition
- Amaurosis Fugax
- Intervention (Drug)
- Revacept
- Intervention (Drug)
- Placebo
- Lead sponsor
- AdvanceCor GmbH
Record details
- Record id
cardio:ct-nct01645306- Content hash
0e7cb4158c18235280d6f66cb4c9dfb3541987a5703c4a95cb59eb48d952c79f